Should I buy Bristol-Myers Squibb stock in 2025?

Why trust HelloSafe?

At HelloSafe, our expert has been monitoring the performance of Bristol-Myers Squibb for more than three years. Every month, over a million users in the United States rely on us to interpret market trends and uncover the best investment opportunities. Our analyses are intended for informational purposes only and do not constitute investment advice. In line with our ethical charter, we have never been, and will never be, compensated by Bristol-Myers Squibb.

What is Bristol-Myers Squibb?

How much is Bristol-Myers Squibb stock?

The price of Bristol-Myers Squibb stock is declining this week. Currently trading at $41.17, the stock is down 1.13% in the last 24 hours and has fallen 2.75% over the past seven days. Bristol-Myers Squibb holds a market capitalization of $83.85 billion, with an average 3-month volume of 13.7 million shares. The P/E ratio stands at 12.74, while investors benefit from a dividend yield of 5.68%. The stock’s beta of 0.44 suggests lower volatility compared to the broader market. As uncertain market conditions persist, Bristol-Myers Squibb’s steady dividend yield may offer a point of stability for careful investors.

Our full analysis on Bristol-Myers Squibb stock

After an in-depth review of Bristol-Myers Squibb’s (NYSE: BMY) recent earnings, comprehensive stock performance over the last three years, and evaluation of competitive positioning, our analysis—leveraging both advanced financial indicators and proprietary multi-source algorithms—offers fresh insight into this industry stalwart. Incorporating technical, fundamental, and market intelligence, one key question stands out: So, why might Bristol-Myers Squibb stock once again become a strategic entry point into the healthcare and biopharmaceutical sector in 2025?

Recent Performance and Market Context

Bristol-Myers Squibb’s share price has weathered significant volatility over the past 36 months, reflecting sectorwide shifts, evolving investor sentiment, and the dynamic nature of the pharmaceutical pipeline. From its $67+ highs in late 2022, BMY has retraced toward the low $40s in early 2024—trading sharply below its five-year average. Notably, as of June 2024, BMY is consolidating near $43–$44, with YTD returns comparatively underperforming the S&P 500, but diverging favorably from several sector peers also facing patent cliffs.

However, several positive developments have recently buoyed the stock:

• Q1 2024 Results: Revenue of $11.9 billion (slightly ahead of consensus), and adjusted EPS of $1.68, beating expectations.
• Pipeline Progress: Regulatory approvals (notably for Camzyos and Opdualag in additional indications) reinforce the company’s leadership in cardiology and oncology.
• Strategic Acquisitions: The recent Mirati Therapeutics acquisition enhances the oncology pipeline with first-in-class assets.
• Macro Backdrop: The US biopharma sector is enjoying tailwinds from increased healthcare spending, favorable regulatory trends, and strong innovation capital.

Amid sector rotation and renewed focus on quality, Bristol-Myers Squibb’s robust pipeline and execution indicate a potential inflection point. The market appears to be factoring in the post-Revlimid transition, but not fully recognizing the upside from new launches and cost controls.

Technical Analysis

From a technical standpoint, several bullish signals have emerged:

• RSI (Relative Strength Index): The stock recently rebounded from oversold territory (RSI below 30 in early May 2024), signaling a base-building phase and possible reversal.
• MACD (Moving Average Convergence Divergence): The MACD line is turning upward, with a bullish crossover observed in late May.
• Moving Averages:
• The 50-day moving average is flattening after a sustained downtrend, converging with the 100-day, which could signal trend exhaustion and impending mean reversion.
• Price action has established a strong support zone at $42, tested multiple times since March.
• Momentum: Short-term momentum is improving: the recent higher lows and resilience around support suggest that sellers are losing conviction.

These technical patterns—when seen in the context of historical valuation troughs—historically precede sharp medium-term recoveries in BMY.

Fundamental Analysis

Bristol-Myers Squibb’s fundamentals reveal a company that is arguably undervalued relative to both historical averages and peers:

• Revenue & Profitability: Although total revenues declined 1% YoY in Q1 2024 (mainly due to Revlimid patent expiration), sales from new products surged 43%, mitigating the patent cliff effect. Operating margins remain strong, and free cash flow generation is robust (over $8 billion TTM).
• Valuation:
• P/E Ratio: BMY trades at approximately 7.5x forward earnings—well below the large-cap pharma peer average (~13x)—reflecting a market discount related to patent and growth concerns.
• PEG Ratio: With a PEG of 0.85, the risk/reward trade-off appears highly attractive for investors seeking growth at a reasonable price.
• Price/Sales: A P/S of just 2.2 underscores an undemanding valuation given the company’s pipeline and cash flow capabilities.
• Balance Sheet & Dividends: Net debt/EBITDA is a manageable 2x. The company maintains a healthy quarterly dividend ($0.60/share, yield near 5.5%), which is well-covered and a clear sign of financial resilience.
• Innovation & Brand Strength: With leading franchises in oncology (Opdivo, Yervoy), cardiovascular (Eliquis), and immunology (Sotyktu), BMY maintains strong market share and high-barrier differentiation.
• Strategic Expansion: Recent bolt-on acquisitions (Karuna, Mirati, RayzeBio) add high-potential assets, further diversifying mid- and late-stage pipelines.

Overall, the current trading range seems to represent an excellent opportunity, where the market’s prevailing skepticism is arguably overdone relative to Bristol-Myers’ proven innovation, financial strength, and adaptability.

Volume and Liquidity

A closer look at trading activity confirms that Bristol-Myers Squibb enjoys strong market participation:

• Sustained Volume: Average daily trading volume exceeds 10 million shares, indicating high liquidity and facilitating efficient price discovery.
• Float Dynamics: With a float of approximately 2.1 billion shares, the stock supports institutional transactions without undue volatility. This deep market ensures ample capacity for both active traders and long-term investors alike.

Importantly, recent volume spikes on up days, coupled with slowing sell-side activity, are often interpreted as signs of accumulating interest—implying that major market participants may be positioning for a rebound.

Catalysts and Positive Outlook

Several forward-looking drivers stand out as potential inflection points for Bristol-Myers Squibb:

• Product Launches: Multiple late-stage pipeline assets are slated for regulatory decisions and market launches in the coming 12–24 months, including deucravacitinib and milvexian, each with blockbuster potential.
• Oncology & Autoimmune Expansion: Further label expansions for existing blockbuster drugs, as well as first-in-class launches from recent M&A deals, could unlock substantial incremental revenue.
• Innovation Pipeline: The company’s R&D intensity is among the top in Big Pharma, with a diversified clinical-stage pipeline – notably in cell therapy, protein degradation, and next-generation immunotherapies.
• ESG Momentum: Bristol-Myers Squibb’s sustainability credentials have improved, with new initiatives in global health equity and carbon neutrality adding appeal for long-horizon funds.
• Sector-wide Tailwinds:
• Continued expansion of global healthcare access.
• Aging population trends driving demand for BMS’s core therapeutic areas.
• US policy backdrop increasingly favorable for innovation-led biopharma.

With significant catalysts on the horizon, the valuation gap between BMY and its peers may begin to close, particularly as pipeline news and quarterly results begin to reflect a new phase of earnings momentum.

Investment Strategies

The current setup arguably justifies renewed, multi-horizon interest in Bristol-Myers Squibb:

• Short-Term: For tactical investors, the cluster of technical supports near $42—along with improving technical momentum—suggests a window for short-term trades targeting a reversion toward the $48–$50 zone.
• Medium-Term: Investors seeking exposure to upcoming catalysts may find the current price an attractive entry ahead of anticipated FDA approvals, data readouts, and accelerated launch ramp-ups in late 2024 and 2025.
• Long-Term: Given its robust pipeline, high free cash flow yield, and commitment to shareholder returns, BMY offers long-horizon investors a rare blend of growth and defensive characteristics. The current multi-year low appears misaligned with the company’s strategic progress and future cash generation potential.

For all horizons, risk-reward seems asymmetrically positive, with the market perhaps underappreciating the resilience of cash flows, growing pipeline, and improving regulatory visibility.

Is It the Right Time to Buy Bristol-Myers Squibb?

Bristol-Myers Squibb’s combination of oversold technicals, inexpensive valuation, leading innovation pipeline, and strong dividend profile create the conditions for a compelling investment case. The company’s diligent navigation of patent headwinds—paired with robust new product acceleration and a clear commitment to shareholder value—signals that the stock may be entering a new bullish phase.

With multiple near-term catalysts, sector tailwinds, and the ability to capture both defensive and growth-oriented capital, BMY seems to represent an excellent opportunity for investors seeking exposure to durable, innovation-driven healthcare.

In summary, while no investment is without risks, Bristol-Myers Squibb’s structural strengths and improving momentum present a rare convergence of value and growth potential—a scenario that justifies renewed optimism and careful consideration as 2025 approaches. The unfolding landscape suggests that BMY is poised not only to recover, but to outperform as sentiment and fundamentals align for the next chapter of shareholder value creation.

How to buy Bristol-Myers Squibb stock in United States?

Buying Bristol-Myers Squibb stock online is simple and secure when you use a regulated U.S. broker. In just a few clicks, you can become a shareholder through two main methods: direct spot buying (owning the physical shares) or trading via Contracts for Difference (CFDs), which allow for leveraged speculation. Both options are easily accessible and designed with investor protection in mind. To make the best choice for your goals, take a look at our detailed broker comparison table further down the page.

Spot buying

A cash or spot purchase means buying actual Bristol-Myers Squibb (BMY) shares and becoming a part-owner of the company. This method is straightforward: you purchase shares at the market price through your broker, who typically charges a fixed commission per order—often around $5 per trade for U.S. investors.

Concrete example

Suppose the current Bristol-Myers Squibb share price is $42 (USD). With a $1,000 investment, and accounting for a $5 brokerage fee, you can buy approximately 23 shares ($995 / $42 ≈ 23 shares).
✔️ Gain scenario:
If the share price rises by 10% to $46.20, your 23 shares are now worth about $1,063.60.
Result: That’s a $100 gross gain (+10%) on your original investment, before taxes and fees.

Trading via CFD

CFD trading allows you to speculate on Bristol-Myers Squibb’s price movements without owning the underlying shares. You can amplify your exposure using leverage—magnifying both potential gains and risks. CFDs involve costs such as the spread (the difference between buy and sell prices) and overnight financing fees if positions are held beyond one trading day.

Concrete example

Imagine you open a CFD position on Bristol-Myers Squibb with a $1,000 margin and 5x leverage. This gives you $5,000 worth of exposure to the stock.
✔️ Gain scenario:
If Bristol-Myers Squibb’s price increases by 8%, your leveraged position gains 8% × 5 = 40%.
Result: You realize a $400 gain on your $1,000 investment (excluding fees and potential losses if the market moves against you).

Final advice

Before investing, it’s essential to compare broker fees (commissions, spreads, overnight costs) and account terms thoroughly. Your best option depends on your experience, risk appetite, and whether you want to own the stock or speculate on its price movements. To help you get started, our brokerage comparison table further down the page can assist you in finding a platform that fits your investment style.

Application

Rates & Fees

Learn More

#1

30+ million users

#1Recommended by Forbes

eToro

Rates & Fees

4.9

Discover

51% of CFD accounts lose money. You will never lose more than your investment.

#2

CFD and Indices Expert

#2

IG

Rates & Fees

4.9

Discover

74% of CFD accounts lose money. Your capital is at risk.

#3

CFD specialist

#3

Avatrade

Rates & Fees

4.8

On the broker's website

Our 7 tips for buying Bristol-Myers Squibb stock

The latest news about Bristol-Myers Squibb

Bristol-Myers Squibb received FDA approval for Augtyro (repotrectinib) for a rare form of lung cancer. On June 15, 2024, the U.S. Food and Drug Administration expanded the approved indications for Augtyro, a medicine owned by Bristol-Myers Squibb, to treat patients with ROS1-positive non-small cell lung cancer. This regulatory milestone strengthens BMY’s oncology franchise and offers access to a treatment aimed at an underserved patient population in the United States, potentially enhancing its competitive positioning in the high-growth U.S. cancer therapeutics market.

The company reaffirmed its full-year 2024 financial guidance, signaling stability despite industry headwinds. During an investor update on June 13, 2024, Bristol-Myers Squibb’s executive leadership confirmed revenue and earnings guidance for the year—including expectations for low single-digit revenue growth and robust free cash flow generation. This announcement helped allay concerns about the near-term impact of generic competition on certain key products and showcased the resilience of BMY’s diversified drug portfolio in the U.S. market.

Bristol-Myers Squibb signed new U.S.-centered research collaborations, expanding its early-stage oncology pipeline. In the past week, BMY unveiled several strategic research partnerships with U.S. academic institutions and biotech startups, focusing on next-generation cancer therapies and immuno-oncology. These alliances are expected to drive long-term innovation, secure future market share, and reinforce the company's presence in the American life sciences ecosystem.

Recent analyst upgrades highlighted growing optimism about BMY’s transformation strategy and pipeline execution. Several major Wall Street firms—including Morgan Stanley and Bank of America—upgraded their outlooks for Bristol-Myers Squibb this week, citing the company’s ability to bring novel drugs to market and leverage its strong U.S. distribution channels. Analysts emphasized management’s consistent execution, expanding R&D pipeline, and potential for margin improvement as key factors supporting their upbeat views.

Bristol-Myers Squibb announced expanded patient access programs in the United States. In response to heightened scrutiny on pharmaceutical affordability in the U.S., BMY this week broadened its suite of patient access and support initiatives for critical therapies, including blood cancer and immune disorder treatments. These initiatives enhance the company’s reputation among healthcare providers and regulators, support sales volumes, and position BMY positively with U.S. stakeholders concerned about equitable access to advanced medicines.

FAQ

P. Laurore

Finance expert

Co-founder of HelloSafe and holder of a Master's degree in finance, Pauline has recognised expertise in personal finance, which she uses to help users better understand and optimise their financial choices. At HelloSafe, Pauline plays a key role in designing clear, educational content on savings, investments and personal finance. Passionate about financial education, Pauline strives, with every piece of content she oversees, to provide reliable, transparent and unbiased information for independent and informed financial management. To this end, she has tested over 100 trading platforms to help internet users make the right choices.